Korea approves first anti-COVID-19 monoclonal antibody treatment
Korea approves first anti-COVID-19 monoclonal antibody treatment 08 February 2021 | News CT-P59 is approved for the treatment of patients aged 60 years and over, or with at least one underlying medical condition, with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID- 19 Photo Credit: Freepik Celltrion Group has announced that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted conditional marketing authorization (MA) for the emergency use of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment candidate. Conditional...
Source: biospectrumasia.com